RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) — AAVIATE

Neovascular Age-Related Macular Degeneration (nAMD) Clinical Trial

Official title:
A Phase 2, Randomized, Dose-escalation, Ranibizumab-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via One or Two Suprachoroidal Space (SCS) Injections in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)

Status Recruiting

Clinical Trial Summary

RGX-314 is being developed as a potential novel one-time gene therapy treatment for the treatment of neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to twelve weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time.

Clinical Trial Description

This phase 2, randomized, dose-escalation study is designed to evaluate the efficacy, safety and tolerability of RGX-314 gene therapy in subjects with nAMD. Approximately 115 participants who meet the inclusion/exclusion criteria will be enrolled into one of 6 cohorts. Participants will be randomized in Cohorts 1 and 2 to receive RGX-314 or ranibizumab control, and participants enrolled in Cohorts 3 through 5 will receive RGX-314. Participants enrolled in Cohort 6 will receive RGX-314 and will be randomized to one of two different post-procedural steroid regimens. Cohort 1 will evaluate RGX-314 Dose 1, Cohorts 2 and 3 will evaluate RGX-314 Dose 2, and Cohorts 4, 5, and 6 will evaluate RGX-314 Dose 3. Participants will be evaluated for efficacy, safety and tolerability of RGX-314 throughout the study. ;

Study Design

Related Conditions & MeSH terms

Choroidal Effusions
Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD)
Wet Macular Degeneration

Clinical Trial Details

NCT number	NCT04514653
Study type	Interventional
Source	AbbVie
Contact	Patient Advocacy
Phone	1-866-860-0117
Email	patientadvocacy@regenxbio.com
Status	Recruiting
Phase	Phase 2
Start date	August 25, 2020
Completion date	January 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04543331` - Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
Recruiting	`NCT05904691` - Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration	Phase 1
Completed	`NCT05282004` - Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit	Phase 3
Active, not recruiting	`NCT04764656` - Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal
Completed	`NCT05269966` - Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)	Phase 4
Completed	`NCT05161806` - Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe	Phase 3
Recruiting	`NCT04657289` - A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)	Phase 3
Recruiting	`NCT06116890` - Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration	Phase 2
Recruiting	`NCT06075147` - The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
Terminated	`NCT04746963` - Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration	Phase 1/Phase 2
Recruiting	`NCT05769153` - Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)	Phase 1/Phase 2
Enrolling by invitation	`NCT05210803` - Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
Not yet recruiting	`NCT06398080` - An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
Active, not recruiting	`NCT05989126` - Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.